Cargando…
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial
IMPORTANCE: Statistically significant overall survival (OS) benefits of CDK4 and CDK6 inhibitors in combination with fulvestrant for hormone receptor (HR)–positive, ERBB2 (formerly HER2)-negative advanced breast cancer (ABC) in patients regardless of menopausal status after prior endocrine therapy (...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777264/ https://www.ncbi.nlm.nih.gov/pubmed/31563959 http://dx.doi.org/10.1001/jamaoncol.2019.4782 |
_version_ | 1783456595142770688 |
---|---|
author | Sledge, George W. Toi, Masakazu Neven, Patrick Sohn, Joohyuk Inoue, Kenichi Pivot, Xavier Burdaeva, Olga Okera, Meena Masuda, Norikazu Kaufman, Peter A. Koh, Han Grischke, Eva-Maria Conte, PierFranco Lu, Yi Barriga, Susana Hurt, Karla Frenzel, Martin Johnston, Stephen Llombart-Cussac, Antonio |
author_facet | Sledge, George W. Toi, Masakazu Neven, Patrick Sohn, Joohyuk Inoue, Kenichi Pivot, Xavier Burdaeva, Olga Okera, Meena Masuda, Norikazu Kaufman, Peter A. Koh, Han Grischke, Eva-Maria Conte, PierFranco Lu, Yi Barriga, Susana Hurt, Karla Frenzel, Martin Johnston, Stephen Llombart-Cussac, Antonio |
author_sort | Sledge, George W. |
collection | PubMed |
description | IMPORTANCE: Statistically significant overall survival (OS) benefits of CDK4 and CDK6 inhibitors in combination with fulvestrant for hormone receptor (HR)–positive, ERBB2 (formerly HER2)-negative advanced breast cancer (ABC) in patients regardless of menopausal status after prior endocrine therapy (ET) has not yet been demonstrated. OBJECTIVE: To compare the effect of abemaciclib plus fulvestrant vs placebo plus fulvestrant on OS at the prespecified interim of MONARCH 2 (338 events) in patients with HR-positive, ERBB2-negative advanced breast cancer that progressed during prior ET. DESIGN, SETTING, AND PARTICIPANTS: MONARCH 2 was a global, randomized, placebo-controlled, double-blind phase 3 trial of abemaciclib plus fulvestrant vs placebo plus fulvestrant for treatment of premenopausal or perimenopausal women (with ovarian suppression) and postmenopausal women with HR-positive, ERBB2-negative ABC that progressed during ET. Patients were enrolled between August 7, 2014, and December 29, 2015. Analyses for this report were conducted at the time of database lock on June 20, 2019. INTERVENTIONS: Patients were randomized 2:1 to receive abemaciclib or placebo, 150 mg, every 12 hours on a continuous schedule plus fulvestrant, 500 mg, per label. Randomization was stratified based on site of metastasis (visceral, bone only, or other) and resistance to prior ET (primary vs secondary). MAIN OUTCOMES AND MEASURES: The primary end point was investigator-assessed progression-free survival. Overall survival was a gated key secondary end point. The boundary P value for the interim analysis was .02. RESULTS: Of 669 women enrolled, 446 (median [range] age, 59 [32-91] years) were randomized to the abemaciclib plus fulvestrant arm and 223 (median [range] age, 62 [32-87] years) were randomized to the placebo plus fulvestrant arm. At the prespecified interim, 338 deaths (77% of the planned 441 at the final analysis) were observed in the intent-to-treat population, with a median OS of 46.7 months for abemaciclib plus fulvestrant and 37.3 months for placebo plus fulvestrant (hazard ratio [HR], 0.757; 95% CI, 0.606-0.945; P = .01). Improvement in OS was consistent across all stratification factors. Among stratification factors, more pronounced effects were observed in patients with visceral disease (HR, 0.675; 95% CI, 0.511-0.891) and primary resistance to prior ET (HR, 0.686; 95% CI, 0.451-1.043). Time to second disease progression (median, 23.1 months vs 20.6 months), time to chemotherapy (median, 50.2 months vs 22.1 months), and chemotherapy-free survival (median, 25.5 months vs 18.2 months) were also statistically significantly improved in the abemaciclib arm vs placebo arm. No new safety signals were observed for abemaciclib. CONCLUSIONS AND RELEVANCE: Treatment with abemaciclib plus fulvestrant resulted in a statistically significant and clinically meaningful median OS improvement of 9.4 months for patients with HR-positive, ERBB2-negative ABC who progressed after prior ET regardless of menopausal status. Abemaciclib substantially delayed the receipt of subsequent chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02107703 |
format | Online Article Text |
id | pubmed-6777264 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-67772642019-10-23 The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial Sledge, George W. Toi, Masakazu Neven, Patrick Sohn, Joohyuk Inoue, Kenichi Pivot, Xavier Burdaeva, Olga Okera, Meena Masuda, Norikazu Kaufman, Peter A. Koh, Han Grischke, Eva-Maria Conte, PierFranco Lu, Yi Barriga, Susana Hurt, Karla Frenzel, Martin Johnston, Stephen Llombart-Cussac, Antonio JAMA Oncol Original Investigation IMPORTANCE: Statistically significant overall survival (OS) benefits of CDK4 and CDK6 inhibitors in combination with fulvestrant for hormone receptor (HR)–positive, ERBB2 (formerly HER2)-negative advanced breast cancer (ABC) in patients regardless of menopausal status after prior endocrine therapy (ET) has not yet been demonstrated. OBJECTIVE: To compare the effect of abemaciclib plus fulvestrant vs placebo plus fulvestrant on OS at the prespecified interim of MONARCH 2 (338 events) in patients with HR-positive, ERBB2-negative advanced breast cancer that progressed during prior ET. DESIGN, SETTING, AND PARTICIPANTS: MONARCH 2 was a global, randomized, placebo-controlled, double-blind phase 3 trial of abemaciclib plus fulvestrant vs placebo plus fulvestrant for treatment of premenopausal or perimenopausal women (with ovarian suppression) and postmenopausal women with HR-positive, ERBB2-negative ABC that progressed during ET. Patients were enrolled between August 7, 2014, and December 29, 2015. Analyses for this report were conducted at the time of database lock on June 20, 2019. INTERVENTIONS: Patients were randomized 2:1 to receive abemaciclib or placebo, 150 mg, every 12 hours on a continuous schedule plus fulvestrant, 500 mg, per label. Randomization was stratified based on site of metastasis (visceral, bone only, or other) and resistance to prior ET (primary vs secondary). MAIN OUTCOMES AND MEASURES: The primary end point was investigator-assessed progression-free survival. Overall survival was a gated key secondary end point. The boundary P value for the interim analysis was .02. RESULTS: Of 669 women enrolled, 446 (median [range] age, 59 [32-91] years) were randomized to the abemaciclib plus fulvestrant arm and 223 (median [range] age, 62 [32-87] years) were randomized to the placebo plus fulvestrant arm. At the prespecified interim, 338 deaths (77% of the planned 441 at the final analysis) were observed in the intent-to-treat population, with a median OS of 46.7 months for abemaciclib plus fulvestrant and 37.3 months for placebo plus fulvestrant (hazard ratio [HR], 0.757; 95% CI, 0.606-0.945; P = .01). Improvement in OS was consistent across all stratification factors. Among stratification factors, more pronounced effects were observed in patients with visceral disease (HR, 0.675; 95% CI, 0.511-0.891) and primary resistance to prior ET (HR, 0.686; 95% CI, 0.451-1.043). Time to second disease progression (median, 23.1 months vs 20.6 months), time to chemotherapy (median, 50.2 months vs 22.1 months), and chemotherapy-free survival (median, 25.5 months vs 18.2 months) were also statistically significantly improved in the abemaciclib arm vs placebo arm. No new safety signals were observed for abemaciclib. CONCLUSIONS AND RELEVANCE: Treatment with abemaciclib plus fulvestrant resulted in a statistically significant and clinically meaningful median OS improvement of 9.4 months for patients with HR-positive, ERBB2-negative ABC who progressed after prior ET regardless of menopausal status. Abemaciclib substantially delayed the receipt of subsequent chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02107703 American Medical Association 2019-09-29 2020-01 /pmc/articles/PMC6777264/ /pubmed/31563959 http://dx.doi.org/10.1001/jamaoncol.2019.4782 Text en Copyright 2019 Sledge GW Jr et al. JAMA Oncology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the CC-BY-NC-ND License. |
spellingShingle | Original Investigation Sledge, George W. Toi, Masakazu Neven, Patrick Sohn, Joohyuk Inoue, Kenichi Pivot, Xavier Burdaeva, Olga Okera, Meena Masuda, Norikazu Kaufman, Peter A. Koh, Han Grischke, Eva-Maria Conte, PierFranco Lu, Yi Barriga, Susana Hurt, Karla Frenzel, Martin Johnston, Stephen Llombart-Cussac, Antonio The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial |
title | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial |
title_full | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial |
title_fullStr | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial |
title_full_unstemmed | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial |
title_short | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial |
title_sort | effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, erbb2-negative breast cancer that progressed on endocrine therapy—monarch 2: a randomized clinical trial |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777264/ https://www.ncbi.nlm.nih.gov/pubmed/31563959 http://dx.doi.org/10.1001/jamaoncol.2019.4782 |
work_keys_str_mv | AT sledgegeorgew theeffectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT toimasakazu theeffectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT nevenpatrick theeffectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT sohnjoohyuk theeffectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT inouekenichi theeffectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT pivotxavier theeffectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT burdaevaolga theeffectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT okerameena theeffectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT masudanorikazu theeffectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT kaufmanpetera theeffectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT kohhan theeffectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT grischkeevamaria theeffectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT contepierfranco theeffectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT luyi theeffectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT barrigasusana theeffectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT hurtkarla theeffectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT frenzelmartin theeffectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT johnstonstephen theeffectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT llombartcussacantonio theeffectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT sledgegeorgew effectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT toimasakazu effectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT nevenpatrick effectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT sohnjoohyuk effectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT inouekenichi effectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT pivotxavier effectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT burdaevaolga effectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT okerameena effectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT masudanorikazu effectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT kaufmanpetera effectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT kohhan effectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT grischkeevamaria effectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT contepierfranco effectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT luyi effectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT barrigasusana effectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT hurtkarla effectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT frenzelmartin effectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT johnstonstephen effectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial AT llombartcussacantonio effectofabemaciclibplusfulvestrantonoverallsurvivalinhormonereceptorpositiveerbb2negativebreastcancerthatprogressedonendocrinetherapymonarch2arandomizedclinicaltrial |